A Pilot Study of LN-144 Immunotherapy in People with Metastatic Uveal Melanoma


Full Title

A Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients with Metastatic Uveal Melanoma


Researchers in this study are exploring the feasibility of making an immunotherapy in a laboratory using white blood cells (called lymphocytes or T cells) collected from the tumor of a patient with metastatic uveal melanoma. This is called autologous tumor-infiltrating lymphocyte (TIL) therapy. The TIL therapy being assessed in this study is called LN-144, and it is designed to activate white blood cells to attack the tumor.

The investigators want to see if it is practical to make LN-144 from participants’ T cells and determine if the treatment is safe. LN-144 is given intravenously (by vein).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have metastatic uveal melanoma that has gotten worse despite treatment.
  • Patients must have at least one lesion 1.5 cm in size or more from which to collect T cells.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people age 18 and older.


For more information about this study and to ask about eligibility, please contact the office of Dr. Alexander Shoushtari at 646-888-4161.




Phase I (phase 1)

Disease Status

Newly Diagnosed & Relapsed/Refractory